Lenacapavir long-acting

Phase 3

DDuke University

Lenacapavir long-acting is one of 5 therapeutic programs targeting HIV Prevention. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HIV PreventionRecruiting

HIV PreventionPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in HIV Prevention

#DrugCompanyPhaseTrials

F/TDF

Gilead

Phase 3

1 2

Lenacapavir long-acting

DDuke University

Phase 3

1 3

Alhydrogel Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 4

GLA-SE Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 5

Pre-Exposure Prophylaxis (prep)

NNew York University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedRecruiting

HIV Prevention

NCT07218211

Clinical

Trials by Indication[1]

HIV Prevention1 trial

INCLUSION - Enhancing PrEP Uptake and Retention Among Latine Transgender Women and Gay, Bisexual, and Other Men Who Have Sex With Men in the South Using Long-Acting Injectable PrEP

Recruiting·DDuke University·Approved·NCT07218211·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lenacapavir long-acting. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lenacapavir long-acting. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Duke University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: DDuke University

Lenacapavir long-acting

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

HIV Prevention1 trial

References

Drug Info

Quick Facts

Related News